International Stem Cell Quick Ratio (ISCO) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
International Stem Cell Corporation  (ISCO)

International Stem Cell's Quick Ratio

ISCO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


International Stem Cell's Cash & cash equivalent grew by 16.72 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in International Stem Cell's Quick Ratio to 0.22, Quick Ratio remained below International Stem Cell Corporation average.

Within Major Pharmaceutical Preparations industry 413 other companies have achieved higher Quick Ratio than International Stem Cell in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2994 to 3164.

Explain Quick Ratio?
How much Cash & cash equivalents ISCO´s has?
What are ISCO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ISCO Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 15.42 % -1.16 % -2.33 % -1.34 % -14.05 %
Y / Y Cash & cash equivalent Change 18.37 % -35.74 % -19.27 % -26.09 % -28.68 %
Quick Ratio MRQ 0.22 0.18 0.22 0.21 0.21
ISCO's Total Ranking # 3164 # 2994 # 3166 # 2794 #
Seq. Current Liabilities Change -1.29 % 10.26 % -1.63 % 7.8 % -15.47 %
Seq. Cash & cash equivalent Change 16.72 % -6.04 % 2.8 % 5 % -36.64 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 414
Healthcare Sector # 812
Overall Market # 3164


Quick Ratio Statistics
High Average Low
3.66 0.48 0.03
(Mar 31 2012)   (Dec 31 2016)




Financial Statements
International Stem Cell's Current Liabilities $ 5 Millions Visit ISCO's Balance sheet
International Stem Cell's Cash & cash equivalent $ 1 Millions Visit ISCO's Balance sheet
Source of ISCO's Sales Visit ISCO's Sales by Geography


Cumulative International Stem Cell's Quick Ratio

ISCO's Quick Ratio for the trailling 12 Months

ISCO Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 2.31 % -4.8 % -3.79 % -3.95 % -3.45 %
Y / Y Cash & cash equivalent TTM Growth -18.9 % -27.79 % -16.92 % -18 % -13.79 %
Quick Ratio TTM 0.21 0.2 0.23 0.24 0.26
Total Ranking TTM # 4126 # 3184 # 3118 # 3219 #
Seq. Current Liabilities TTM Growth 3.58 % -0.32 % -0.58 % -0.33 % -3.61 %
Seq. Cash & cash equivalent TTM Growth 4.43 % -11.98 % -5.19 % -6.95 % -7.01 %

Quick ratio ranking by company, industry and sector >> Back to ISCO Financial Strength Comparisons >> Go to Compare ISCO Quick Ratio to its Competitors

On the trailing twelve months basis ISCO Cash & cash equivalent increased by 18.37 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in International Stem Cell's Quick Ratio to 0.21, Quick Ratio remained below ISCO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than International Stem Cell. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3184 to 4126.

Explain Quick Ratio?
How much Cash & cash equivalents ISCO´s has?
What are ISCO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 444
Healthcare Sector # 915
Within the Market # 4126


trailing twelve months Quick Ratio Statistics
High Average Low
1.73 0.29 0.06
(Sep 30 2012)   (Mar 31 2018)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Eton Pharmaceuticals Inc   0.59 $ 26.845  Millions$ 45.124  Millions
Kura Oncology Inc   0.59 $ 70.242  Millions$ 118.193  Millions
Allarity Therapeutics Inc   0.59 $ 16.982  Millions$ 28.579  Millions
Bristol myers Squibb Company  0.59 $ 11,067.000  Millions$ 18,659.000  Millions
Prestige Consumer Healthcare Inc   0.58 $ 89.127  Millions$ 153.806  Millions
Biora Therapeutics Inc   0.57 $ 21.906  Millions$ 38.687  Millions
Matinas Biopharma Holdings Inc   0.56 $ 0.761  Millions$ 1.350  Millions
Karyopharm Therapeutics Inc   0.56 $ 75.225  Millions$ 134.233  Millions
Journey Medical Corp  0.56 $ 25.643  Millions$ 45.770  Millions
Nektar Therapeutics  0.55 $ 39.267  Millions$ 70.985  Millions
Supernus Pharmaceuticals inc   0.52 $ 180.145  Millions$ 347.378  Millions
Citius Oncology Inc  0.50 $ 16.564  Millions$ 33.152  Millions
Verrica Pharmaceuticals Inc   0.50 $ 11.198  Millions$ 22.442  Millions
Aytu Biopharma Inc  0.48 $ 26.308  Millions$ 54.659  Millions
Jupiter Neurosciences Inc   0.47 $ 1.522  Millions$ 3.251  Millions
Aeon Biopharma inc   0.47 $ 3.431  Millions$ 7.342  Millions
Evolus Inc   0.46 $ 45.170  Millions$ 98.731  Millions
Biomarin Pharmaceutical Inc  0.45 $ 874.005  Millions$ 1,927.164  Millions
Pds Biotechnology Corp  0.45 $ 5.596  Millions$ 12.377  Millions
Biofrontera Inc   0.44 $ 4.659  Millions$ 10.541  Millions
Beyondspring Inc   0.43 $ 10.361  Millions$ 23.834  Millions
Organon and Co   0.43 $ 1,132.000  Millions$ 2,616.000  Millions
Gossamer Bio Inc   0.41 $ 57.026  Millions$ 137.783  Millions
Bausch Health Companies Inc   0.39 $ 1,825.000  Millions$ 4,687.000  Millions
Johnson and Johnson  0.38 $ 21,094.000  Millions$ 54,895.000  Millions
Ultragenyx Pharmaceutical Inc   0.36 $ 125.000  Millions$ 351.000  Millions
Vanda Pharmaceuticals Inc   0.34 $ 56.119  Millions$ 164.026  Millions
Ainos Inc   0.29 $ 1.423  Millions$ 4.928  Millions
Elanco Animal Health Incorporated  0.29 $ 530.000  Millions$ 1,852.000  Millions
Provectus Biopharmaceuticals Inc   0.27 $ 1.157  Millions$ 4.234  Millions

Date modified: 2026-09-26T07:02:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.